title: The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction.
abstract: OBJECTIVE
  We investigated single dose and steady-state pharmacokinetics of moxifloxacin in eight venovenous haemodialysis patients.
  
  
  METHODS
  Plasma, dialysate and urine pharmacokinetic parameters for moxifloxacin and its main metabolites were calculated after single and multiple (7 days) dosing with 400 mg day(-1).
  
  
  RESULTS
  Moxifloxacin pharmacokinetics after a single dose and at steady state (multidose day 7) were comparable in patients with impaired renal function and healthy subjects (geometric mean/%CV AUC mg l(-1) h single dose 37.0/24.3 in haemodialysis patients vs. 29.8/22.6 in healthy subjects, 95% CI for ratio of haemodialysis patients to healthy subjects 99.34%, 154.60%; steady state 40.4/29.1 haemodialysis patients vs. 33.9/20.1 in healthy subjects, 95% CI for ratio of haemodialysis patients to healthy subjects 90/39%, 156.93%). In haemodialysis patients plasma concentrations of moxifloxacin at steady-state were elevated compared with those after a single 400 mg dose (AUC mg l(-1) h, geometric mean/%CV, 40.4/29.1) compared with 37.0/24.3; 95% CI for ratio of steady-state to single dose 87.29%, 136.52%, as were concentrations of metabolite M1 3.21/34.6 compared with 2.02/45.3, 95% CI for ratio of steady state to single dose 14.21%, 175.07%. Haemodialysis cleared about 9% of the dose as unchanged moxifloxacin.
  
  
  CONCLUSIONS
  No dose adjustments are required for venovenous haemodialysis patients on oral moxifloxacin therapy.
authors.affiliation: BAYER HealthCare AG, Research Center, Wuppertal, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Stass
authors.forename: S
authors.initials: S
authors.lastname: Bührmann
authors.forename: A
authors.initials: A
authors.lastname: Mitchell
authors.forename: D
authors.initials: D
authors.lastname: Kubitza
authors.forename: J-G
authors.initials: JG
authors.lastname: Möller
authors.forename: A
authors.initials: A
authors.lastname: Kribben
authors.forename: R R
authors.initials: RR
authors.lastname: Wenzel
authors.forename: R F
authors.initials: RF
authors.lastname: Schäfers
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001372:Aza Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects / Q000502:physiology; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006435:Renal Dialysis / Q000379:methods*
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin